{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:56:09Z","timestamp":1778154969440,"version":"3.51.4"},"reference-count":58,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T00:00:00Z","timestamp":1439769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK087859"],"award-info":[{"award-number":["K23 DK087859"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R01DK081473\u201001"],"award-info":[{"award-number":["1R01DK081473\u201001"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormalities in mineral metabolism are a universal complication in dialysis patients and are associated with an increased risk of cardiovascular disease and mortality. Hyperphosphatemia, increased fibroblast growth factor 23 levels and secondary hyperparathyroidism are all strongly associated with adverse outcomes in end stage renal disease (<jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>) and most treatment strategies target these parameters. Over the past few years, new therapies have emerged for the treatment of abnormalities of mineral metabolism in <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content> and many are promising. This article will review these new therapeutic options including the potential advantages and disadvantages compared to existing therapies.<\/jats:p>","DOI":"10.1111\/sdi.12412","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T07:05:39Z","timestamp":1439795139000},"page":"610-619","source":"Crossref","is-referenced-by-count":4,"title":["Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease"],"prefix":"10.1111","volume":"28","author":[{"given":"Jessica","family":"Kendrick","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension University of Colorado School of Medicine Aurora Colorado"},{"name":"Denver Health Medical Center Denver Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension University of Colorado School of Medicine Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,17]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"USRDS 2014 Annual Data Report: Atlas of End\u2010Stage Renal Disease in the United States","author":"US Renal Data System","year":"2014"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-9-2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02500607"},{"issue":"113","key":"e_1_2_7_5_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group","year":"2009","journal-title":"Kidney Int"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00600.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.02.298"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000170783"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912522"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000182446"},{"key":"e_1_2_7_12_1","first-page":"389","article-title":"Mangesium\u2010its role in CKD","volume":"33","author":"De franciso Al M","year":"2013","journal-title":"Nefrologia"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321837"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.222"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/12.9.2036","article-title":"Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium","volume":"12","author":"Tzanakis I","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2009.00364.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00898.x"},{"key":"e_1_2_7_18_1","first-page":"1147","article-title":"Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation\u2010safety, efficacy and patient adherence","volume":"7","author":"Lloret MJ","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000149239"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944713513061"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60897-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1681\/ASN.V1061274","article-title":"New phosphate binding agents: ferric compounds","volume":"10","author":"Hsu CH","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/08860229909045184"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357011775596"},{"key":"e_1_2_7_25_1","unstructured":"Velphoro package insert 2014. Available athttp:\/\/velphoro.us accessed March 2015."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP74004"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08230811"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.58"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv006"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.2.265"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.11.041"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080842"},{"key":"e_1_2_7_34_1","unstructured":"Auryxia package insert. Available at:http:\/\/auryxia.com accessed March 2015."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.020"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354717"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06910714"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-12-200712180-00004"},{"key":"e_1_2_7_39_1","unstructured":"Amgen announces positive phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis. Available at:http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2014&releaseID=1948573 accessed March 31 2015."},{"key":"e_1_2_7_40_1","unstructured":"Amgen announces positive top\u2010line results from second phase 3 study of AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis. Available at:http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2014&releaseID=1959215 accessed March 31 2015"},{"key":"e_1_2_7_41_1","unstructured":"Amgen announces positive results from head\u2010to\u2010head study comparing the efficacy and safety of AMG 416 with cinacalcet in patients with secondary hyperparathyroidism receiving hemodialysis.http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?releaseID=2020209 accessed March 31 2015."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00308.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706130"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010121224"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.844506"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN107991"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.001"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.11.007"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09250912"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq053"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12319"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr384"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03630509"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12326"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013876"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61405"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3034"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:59:56Z","timestamp":1695985196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,17]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/sdi.12412"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12412","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,17]]}}}